Skip to main content

Generic Adasuve Availability

Last updated on Jan 11, 2023.

Adasuve is a brand name of loxapine, approved by the FDA in the following formulation(s):

ADASUVE (loxapine - powder;inhalation)

  • Manufacturer: ALEXZA PHARMS
    Approval date: December 21, 2012
    Strength(s): 10MG [RLD]

Has a generic version of Adasuve been approved?

No. There is currently no therapeutically equivalent version of Adasuve available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adasuve. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Delivery of antipsychotics through an inhalation route
    Patent 6,716,416
    Issued: April 6, 2004
    Inventor(s): Joshua D.; Rabinowitz & Alejandro C.; Zaffaroni
    Assignee(s): Alexza Molecular Delivery Corporation

    The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antipsychotic through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antipsychotic; and, b) a device that forms an antipsychotic containing aerosol from the composition, for inhalation by the mammal.

    Patent expiration dates:

    • May 20, 2022
      ✓ 
      Drug product
  • Method and apparatus for vaporizing a compound
    Patent 7,458,374
    Issued: December 2, 2008
    Inventor(s): Hale; Ron L. & Song; Soonho & Quintana; Reynaldo J. & Zaffaroni; Alejandro C. & Rabinowitz; Joshua D.
    Assignee(s): Alexza Pharmaceuticals, Inc.

    Disclosed is a method and device for rapid heating of a coated substance which preferably includes a drug to vaporized for inhalation therapy. A device in accordance with the present invention preferably includes a substrate which has an interior surface surrounding an interior region and an exterior surface upon which the coated substance is to be adhered. Though the substrate is preferably metallic, it does not need to be. A combustible element is placed in the interior region of the rigid substrate and an igniter is connected to the combustible element. The igniter is for initiating oxidation of the combustible element. Preferably, the coated substance is vaporized inside of a housing to allow the vaporized drug to aerosolize and be inhaled by a user.

    Patent expiration dates:

    • August 18, 2024
      ✓ 
      Drug product
  • Method of forming an aerosol for inhalation delivery
    Patent 7,537,009
    Issued: May 26, 2009
    Inventor(s): Hale; Ron L. & Hodges; Craig C. & Lloyd; Peter M. & Mufson; Daniel & Rogers; Daniel D. & Song; Soonho & Wensley; Martin J. & Myers; Daniel J. & McKinney; Jeffrey A. & Quintana; Reynaldo J. & Rabinowitz; Joshua D.
    Assignee(s): Alexza Pharmaceuticals, Inc.

    The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000° C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10 μ thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.

    Patent expiration dates:

    • October 28, 2024
      ✓ 
      Drug product
  • Method of forming an aerosol for inhalation delivery
    Patent 8,074,644
    Issued: December 13, 2011
    Inventor(s): Hale; Ron L. & Hodges; Craig C. & Lloyd; Peter M. & Mufson; Daniel & Rogers; Daniel D. & Song; Soonho & Wensley; Martin J. & Myers; Daniel J. & McKinney; Jeffrey A. & Quintana; Reynaldo J. & Rabinowitz; Joshua D.
    Assignee(s): Alexza Pharmaceuticals, Inc.

    The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. In a method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug at a rate greater than 1000° C./s, thereby forming an vapor; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10μ thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another method aspect of the present invention, a method of forming an aerosol for use in inhalation therapy is provided. The method involves the following steps: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.1 mg; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy.

    Patent expiration dates:

    • July 25, 2022
      ✓ 
      Drug product
  • Self-contained heating unit and drug-supply unit employing same
    Patent 8,387,612
    Issued: March 5, 2013
    Assignee(s): Alexza Pharmaceuticals, Inc.

    Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

    Patent expiration dates:

    • October 23, 2026
      ✓ 
      Drug product
  • Self-contained heating unit and drug-supply unit employing same
    Patent 8,991,387
    Issued: March 31, 2015
    Assignee(s): Alexza Pharmaceuticals, Inc.

    Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

    Patent expiration dates:

    • May 21, 2024
      ✓ 
      Drug product
  • Self-contained heating unit and drug-supply unit employing same
    Patent 9,370,629
    Issued: June 21, 2016
    Assignee(s): ALEXZA PHARMACEUTICALS, INC.

    Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

    Patent expiration dates:

    • May 20, 2024
      ✓ 
      Drug product

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.